Literature DB >> 25962708

Intrahepatic mass-forming cholangiocarcinoma: enhancement pattern on Gd-BOPTA-MRI with emphasis of hepatobiliary phase.

Giuseppe Mamone1, Gianluca Marrone2, Settimo Caruso2, Vincenzo Carollo2, Giovanni Gentile2, Francesca Crino'2, Mariapina Milazzo2, Angelo Luca2.   

Abstract

PURPOSE: To describe the Gd-BOPTA MRI findings of intrahepatic mass-forming type cholangiocarcinomas (IMCs), with emphasis on the hepatobiliary phase (HBP).
METHODS: We reviewed retrospectively 29 IMC patients who underwent Gd-BOPTA-MRI between June, 2004 and June, 2014. Images were acquired prior to, and after, administration of 15-20 mL of Gd-BOPTA in the dynamic phase (arterial phase, portal venous phase, and 3-5 min phase), 10-15-min late phase, and 2-3 h HBP phase.
RESULTS: In the dynamic phase, 27 (93%) lesions showed a peripheral rim-like enhancement in the arterial and portal venous phases, followed by progressive filling-in on the delayed images. In 14 (56%) cases, a hypointense peripheral rim was identified in the 10-15-min late phase, delineating a target pattern. In the HBP, the cholangiocarcinoma showed a diffuse, mainly central and inhomogeneous enhancement (cloud of enhancement) in 28 (96%) patients; in 23 (79%) cases, there was an association between cloud appearance and a hypointense peripheral rim, showing a target pattern.
CONCLUSIONS: Gd-BOPTA MRI pattern of IMC on dynamic study is similar to that of conventional extracellular agents, that is peripheral enhancement with progressive and concentric filling of contrast material on delayed phases. At 10-15 min delayed phases, IMC shows often a peripheral hypointense rim consistent with a target appearance. In the HBP, due to progressive central enhancement (cloud) and peripheral hypointense rim, an higher number of tumors show a target appearance; this pattern is not specific and would also be expected to be seen in metastases from adenocarcinoma.

Entities:  

Keywords:  Gd-BOPTA; Hepatobiliary phase (HBP); Intrahepatic mass-forming cholangiocarcinoma (IMC); Liver; MRI

Mesh:

Substances:

Year:  2015        PMID: 25962708     DOI: 10.1007/s00261-015-0445-5

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  6 in total

1.  Values of MRI Imaging Presentations in the Hepatobiliary Phase, DWI and T2WI Sequences in Predicting Pathological Grades of Intrahepatic Mass-Forming Cholangiocarcinoma.

Authors:  Li-Hong Xing; Li-Yong Zhuo; Jia-Ning Wang; Yan Zhang; Feng-Ying Zhu; Chu Wang; Xiao-Ping Yin; Bu-Lang Gao
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

2.  DWI Combined With Hepatobiliary-Phase Enhanced Imaging Can Better Differentiate Cholangiocarcinoma From Atypical Liver Abscesses.

Authors:  Li-Hong Xing; Li-Yong Zhuo; Yu Zhang; Xi Ma; Ze-Peng Ma; Ying-Jia Zhao; Xiao-Ping Yin; Bu-Lang Gao
Journal:  Front Oncol       Date:  2022-05-13       Impact factor: 5.738

3.  Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma.

Authors:  E Reizine; M Ronot; M Ghosn; J Calderaro; N Frulio; P Bioulac-Sage; H Trillaud; V Vilgrain; V Paradis; A Luciani
Journal:  Eur Radiol       Date:  2020-11-04       Impact factor: 5.315

Review 4.  Intrahepatic cholangiocarcinoma: current perspectives.

Authors:  Stefan Buettner; Jeroen LA van Vugt; Jan Nm IJzermans; Bas Groot Koerkamp
Journal:  Onco Targets Ther       Date:  2017-02-22       Impact factor: 4.147

5.  Comparison of the clinical and MRI features of patients with hepatic hemangioma, epithelioid hemangioendothelioma, or angiosarcoma.

Authors:  Zhuangsheng Liu; Lilei Yi; Junhao Chen; Ruqiong Li; Keming Liang; Xiangmeng Chen; Ronggang Li; Wansheng Long
Journal:  BMC Med Imaging       Date:  2020-06-29       Impact factor: 1.930

6.  Atypical Enhancement of Gd-BOPTA on the Hepatobiliary Phase in Hepatic Metastasis from Carcinoid Tumor - Case Report.

Authors:  Patryk Pozowski; Paula Misiak; Kinga Szymańska; Rafał Mazur; Małgorzata Sierpowska; Jurand Silicki; Milena Celmer; Mateusz Łasecki; Aleksander Pawluś; Urszula Zaleska-Dorobisz
Journal:  Am J Case Rep       Date:  2020-09-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.